Biased Agonism: Does It Work?# The Evidence So Far# Two drugs in this comparison -- ecnoglutide and CT-388 -- were specifically engineered with biased agonism to improve tolerability: Ecnoglutide (cAMP-biased at GLP-1R): Discontinuation due to AEs: approximately 2%, among the lowest reported for any GLP-1 agonist Weight loss of 13.2% at 40 weeks is competitive with semaglutide-class efficacy The tolerability-to-efficacy ratio appears favorable CT-388 (signal-biased at both GLP-1R and GIPR): Despite very high Phase 1b GI rates during titration (83% nausea), Phase 2 showed only 5.9% AE discontinuation Weight loss of 22.5% at 48 weeks is among the highest in the field The tolerability-to-efficacy ratio is notable: comparable weight loss to tirzepatide with a lower discontinuation rate What the Data Suggest# The biased agonism hypothesis appears to be supported by early clinical data, though with important caveats: Biased agonists do not eliminate GI side effects -- they may reduce their severity and duration The key metric is discontinuation, not incidence -- a drug with high nausea rates but low discontinuation may indicate transient, manageable symptoms Longer and larger trials are needed -- both ecnoglutide and CT-388 have limited Phase 3 data available Patterns and Insights# More Receptors, More Side Effects# A general pattern emerges: adding receptor targets increases both efficacy and GI side effect burden
Advertisement - Continue Reading Below Pros Absorbs well, leaving skin feeling silky-soft Evens out the skin tone Cons Slightly tacky finish Dr
Across 26,436 total participants, they identified 252 different serious adverse events and calculated the relative risk for each one
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021
It also notes that compounded formulations from licensed 503A pharmacies open up additional cost-effective routes
NAD+ Nasal Spray Starting at $ 83 Dose: 300mg A compounded, needle-free intranasal coenzyme, prescribed at provider discretion
